This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Earnings Season Could Be Great for Novartis (NVS)
by Zacks Equity Research
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
by Kinjel Shah
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Roche's Risdiplam Meets Primary Endpoint in Infants Study
by Zacks Equity Research
Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.
Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe
by Zacks Equity Research
Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
by Zacks Equity Research
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
Is Novartis AG (NVS) A Suitable Pick for Value Investors?
by Zacks Equity Research
Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
by Kinjel Shah
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
by Zacks Equity Research
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
Regeneron's Phase II Candidate Promising in Primary Analysis
by Zacks Equity Research
Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), McDonald's (MCD) and Bristol-Myers Squibb (BMY).
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
by Zacks Equity Research
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
by Zacks Equity Research
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
by Zacks Equity Research
Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
Epizyme (EPZM) Shares Soar on Lead Candidate's Progress
by Zacks Equity Research
Epizyme's (EPZM) shares soar year to date on positive developments for its lead pipeline candidate tazemetostat being evaluated for the treatment of solid tumors and hematological malignancies
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
by Zacks Equity Research
Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.